Testing for immune 'hotspots' can predict risk that breast cancer will return

August 4, 2017, Institute of Cancer Research, London
Micrograph showing a lymph node invaded by ductal breast carcinoma, with extension of the tumour beyond the lymph node. Credit: Nephron/Wikipedia

Scientists have developed a new test that can pick out women at high risk of relapsing from breast cancer within 10 years of diagnosis.

Their study looked for immune cell 'hotspots' in and around tumours, and found that women who had a high number of hotspots were more likely to than those with lower numbers.

The new could help more accurately assess the risk of returning in individual patients, and offer them monitoring or preventative treatment.

Scientists at The Institute of Cancer Research, London, analysed tissue samples from 1,178 women with the most common form of cancer - oestrogen receptor positive breast cancer.

The team created a new, fully automated computer tool to analyse the samples, which were taken as part of a clinical trial at The Royal Marsden NHS Foundation Trust and other hospitals in the UK, comparing two hormone therapies that can help stop cancer recurring after surgery.

The researchers found that when clustered together in hotspots, the chance of relapse within 10 years of starting treatment was 25 per cent higher than when immune cells were evenly dispersed.

The chance of cancer returning within five years was 23 per cent higher in women with immune cell hotspots.

The researchers previously looked at tumour samples from oestrogen receptor-negative breast cancer, and found here that clustering of immune cells had the opposite effect, with hotspots linked to a lower chance of relapse.

The study was published in the Journal of the National Cancer Institute today (Friday), and was funded by the NIHR Biomedical Research Centre at The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research (ICR), with support from Breast Cancer Now, Cancer Research UK, and Wellcome.

Once the is validated, it could be used to help predict the risk of cancer relapse, and to make decisions about the right course of treatment.

The effect of immune hotspots on the chance of relapse could be linked to how the immune system is working in these cancers.

Better understanding of the immune system in breast cancer could in future help unpick why certain immunotherapies work in some patients but not others, and lead to finding new immunotherapy drug targets.

Dr Yinyin Yuan, Team Leader in Computational Pathology at The Institute of Cancer Research, London, said:

"We have developed a new, automated computer tool that makes an assessment of the risk of relapse based on how cells are organised spatially, and whether or not immune cells are clustered together in the tumour.

"In the most common form of breast cancer, oestrogen receptor positive, the presence of hotspots of immune clustered together in the tumour was strongly linked to an increased risk of relapse after hormone treatment.

"Larger studies are needed before an immune hotspot test could come to the clinic, but in future such a test could pick out patients at highest risk of their cancer returning. It might also be possible to predict which patients would respond to immunotherapy.

"The samples used in our study already form part of routine clinical practice, which means that implementing an immune test would be relatively easy and cost-effective."

Professor Paul Workman, Chief Executive of The Institute of Cancer Research, London, said:

"This ingenious new computer-based test automatically analyses breast cancer samples, revealing patterns impossible to detect under the microscope with the human eye. In future, the test could allow us to identify those patients who are at a higher risk of relapse on hormone therapy, and potentially change their treatment.

"What this study also tells us is that the immune system probably has a key role to play in how breast cancer responds to hormone treatment. Measuring the immune response to cancer could be important in future to help identify patients who could benefit from immunotherapy."

Professor Mitch Dowsett, Head of the Ralph Lauren Centre for Breast Cancer Research at The Royal Marsden, said:

"There are a number of molecular tests used in the management of women with early breast cancer but none of these have focussed on the immune aspects of the disease.

We hope these novel findings will enable us to refine the use of those tests further and help us improve the management of the greater than 40,000 women who develop this type of in the UK each year."

Explore further: New breast cancer test links immune 'hotspots' to better survival

Related Stories

New breast cancer test links immune 'hotspots' to better survival

February 27, 2015
Scientists have developed a new test which can predict the survival chances of women with breast cancer by analysing images of 'hotspots' where there has been a fierce immune reaction to a tumour.

Pregnancy not dangerous for women who had breast cancer

June 4, 2017
Becoming pregnant after a diagnosis of breast cancer does not raise the risk of the cancer returning, said the largest study of its kind to date, released Saturday at a major cancer conference.

Researchers quantify immune cells associated with future breast cancer risk

February 8, 2017
Researchers from Mayo Clinic have quantified the numbers of various types of immune cells associated with the risk of developing breast cancer. The findings are published in a study in Clinical Cancer Research.

New treatment hope for women with BRCA1 breast cancers

June 7, 2017
Researchers have found a new way to use immunotherapy, a breakthrough mode of cancer treatment which harnesses the patient's immune system, to treat an aggressive form of breast cancer.

New 'mutation-tracking' blood test could predict breast cancer relapse months in advance

August 26, 2015
Scientists have developed a blood test for breast cancer able to identify which patients will suffer a relapse after treatment, months before tumours are visible on hospital scans.

New biomarker that predicts breast cancer relapse found

May 16, 2011
Researchers from Virginia Commonwealth University Massey Cancer Center have discovered a new biomarker related to the body's immune system that can predict a breast cancer patients' risk of cancer recurrence. This breakthrough ...

Recommended for you

Healthy diets linked to better outcomes in colorectal cancer

October 20, 2018
Colorectal cancer patients who followed healthy diets had a lower risk of death from colorectal cancer and all causes, even those who improved their diets after being diagnosed, according to a new American Cancer Society ...

Why some cancers affect only young women

October 19, 2018
Among several forms of pancreatic cancer, one of them specifically affects women, often young. How is this possible, even though the pancreas is an organ with little exposure to sex hormones? This pancreatic cancer, known ...

Scientists to improve cancer treatment effectiveness

October 19, 2018
Together with researchers from the University of Nantes and the University of Reims Champagne-Ardenne in France, experts from the National Research Nuclear University MEPhI have recently developed a quantum dot-based microarray ...

Mutant cells colonize our tissues over our lifetime

October 18, 2018
By the time we reach middle age, more than half of the oesophagus in healthy people has been taken over by cells carrying mutations in cancer genes, scientists have uncovered. By studying normal oesophagus tissue, scientists ...

Study involving hundreds of patient samples may reveal new treatment options of leukemia

October 17, 2018
After more than five years and 672 patient samples, an OHSU research team has published the largest cancer dataset of its kind for a form of leukemia. The study, "Functional Genomic Landscape of Acute Myeloid Leukemia", published ...

A 150-year-old drug might improve radiation therapy for cancer

October 17, 2018
A drug first identified 150 years ago and used as a smooth-muscle relaxant might make tumors more sensitive to radiation therapy, according to a recent study led by researchers at The Ohio State University Comprehensive Cancer ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.